Targeting HER2: precision oncology for colorectal cancer

Simonetta M. Leto, Francesco Sassi, Irene Catalano, Valter Torri, Giorgia Migliardi, Eugenia R. Zanella, Mark Throsby, Andrea Bertotti, Livio Trusolino, Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas Clinical Cancer Research. ,vol. 21, pp. 5519- 5531 ,(2015) , 10.1158/1078-0432.CCR-14-3066

F. Lédel, M. Hallström, P. Ragnhammar, K. Öhrling, D. Edler, HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome European Journal of Cancer. ,vol. 50, pp. 656- 662 ,(2014) , 10.1016/J.EJCA.2013.11.008

Won‐Suk Lee, Yeon Ho Park, Jung Nam Lee, Jeong‐Heum Baek, Tae‐Hoon Lee, Seung Yeon Ha, Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases Cancer Medicine. ,vol. 3, pp. 674- 680 ,(2014) , 10.1002/CAM4.228

Ramesh K. Ramanathan, Jimmy J. Hwang, William C. Zamboni, Frank A. Sinicrope, Howard Safran, Michael K. Wong, Martin Earle, Adam Brufsky, Terry Evans, Monica Troetschel, Christine Walko, Roger Day, Helen X. Chen, Sydney Finkelstein, Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial Cancer Investigation. ,vol. 22, pp. 858- 865 ,(2004) , 10.1081/CNV-200039645

Jian Ma, Hui Lyu, Jingcao Huang, Bolin Liu, Targeting of erbB3 receptor to overcome resistance in cancer treatment Molecular Cancer. ,vol. 13, pp. 105- 105 ,(2014) , 10.1186/1476-4598-13-105

Samuel A Jacobs, James J Lee, Thomas J George Jr, James L Wade III, Philip J Stella, Ding Wang, Ashwin R Sama, Marc E Buyse, Jodi A Kanyuch, Ashok Srinivasan, Kay L Pogue-Geile, S Rim Kim, Norman Wolmark, Carmen J Allegra, None, Abstract C46: NSABP FC-7: A phase Ib study evaluating neratinib (N) and cetuximab (Cmab) in patients (pts) with quadruple wild-type (quad wt) (KRAS/NRAS/BRAF/PI3KCA wt) metastatic colorectal cancer (mCRC) resistant to Cmab Molecular Cancer Therapeutics. ,vol. 14, ,(2015) , 10.1158/1535-7163.TARG-15-C46

Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M Comoglio, Alberto Bardelli, Silvia Marsoni, Salvatore Siena, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial Lancet Oncology. ,vol. 17, pp. 738- 746 ,(2016) , 10.1016/S1470-2045(16)00150-9

Emanuele Valtorta, Cosimo Martino, Andrea Sartore-Bianchi, Frédérique Penaullt-Llorca, Giuseppe Viale, Mauro Risio, Massimo Rugge, Walter Grigioni, Katia Bencardino, Sara Lonardi, Vittorina Zagonel, Francesco Leone, Johannes Noe, Fortunato Ciardiello, Carmine Pinto, Roberto Labianca, Stefania Mosconi, Claudio Graiff, Giuseppe Aprile, Barbara Frau, Carlo Garufi, Fotios Loupakis, Patrizia Racca, Giuseppe Tonini, Calogero Lauricella, Silvio Veronese, Mauro Truini, Salvatore Siena, Silvia Marsoni, Marcello Gambacorta, None, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study Modern Pathology. ,vol. 28, pp. 1481- 1491 ,(2015) , 10.1038/MODPATHOL.2015.98

Herbert Hurwitz, John D. Hainsworth, Charles Swanton, Edith A. Perez, Christopher Sweeney, Howard A. Burris, David Spigel, Funda Meric-Bernstam, Donald K Strickland, Larry Leon, Melissa Brammer, Mary Stanley Beattie, Ron Bose, Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. Journal of Clinical Oncology. ,vol. 34, pp. 653- 653 ,(2016) , 10.1200/JCO.2016.34.4_SUPPL.653